Flex Single-Use Isolators, Robotic Arms, and PAT: Are We Entering a 5th Generation of Barrier Technology?

For an industry that measures decontamination cycles in minutes now, it's worth remembering that the first full-barrier system needed eighteen hours to sanitize. That was the mid-1990s. Thirty years and roughly four technological generations later, the compounds' barrier technology that exists to contain have changed almost as much as the barriers themselves—and that second fact may matter more than the first.

A MOLECULE PROBLEM, NOT JUST AN ENGINEERING ONE

Barrier technology didn't evolve in a vacuum. Every generation described below was, in part, a response to what the industry was being asked to make.

In the 1990s and early 2000s, the pharmaceutical industry was still predominantly a bulk business: statins, antibiotics, and generics—high-volume, comparatively low-toxicity active ingredients produced in facilities measured in metric tons. Occupational exposure bands, to the extent anyone used them, mostly lived in OEB 12 territory. Containment was a good practice, not an existential requirement.

That changed as the pipeline shifted toward hormonal therapies, steroids, and early oncology compounds—active ingredients potent enough at microgram doses to demand real engineering controls. This is the OEB 3–4 world, and it's roughly where SafeBridge's categorization system and Merck's PB-ECL model matured through the 2000s, each company building its own scale because no shared standard yet existed.

The real inflection point, though, is the one the industry is still living through: the move toward highly cytotoxic payloads, antibody-drug conjugates (ADCs), and targeted therapies for oncology, and—increasingly—cell and gene therapies for neuromuscular and other rare diseases. These aren't bulk products. A batch might be measured in grams, not tons, at a value per gram that can run into the tens of thousands of dollars, targeting patient populations in the hundreds rather than the millions. OEB 5, OEB 6, and containment strategies once reserved for the most exotic laboratory settings are now baseline expectations for a growing share of the pipeline.

This is the demand curve that barrier technology has been chasing, generation after generation: smaller batches, higher potency, higher value per unit, and—critically—far less tolerance for the kind of facility-wide, multiweek changeover that made sense when a plant ran one product for years at a time.

HOW WE GOT HERE: FOUR GENERATIONS OF BARRIER TECHNOLOGY

The clearest account of this history comes from a 2013 industry piece, “Emerging Fourth Generation Barrier Technologies,” which laid out the first three generations plainly and named the fourth as it was happening. It's worth revisiting in full, because the pattern—each generation solving the specific operational pain the last one left behind—is about to repeat itself. 

Two details from that history are worth pulling forward. First, the 4th generation's single-use breakthrough—SUDS, connected via alpha ports on the isolator and beta ports on the disposable bag—solved contamination and changeover risk for the components inside the isolator. It never touched the isolator itself, which stayed rigid stainless steel, expensive to build, and slow to reconfigure. Second, 4th-generation RABS wasn't really a technology story at all; it was mostly the industry agreeing on stricter minimum standards for what could honestly be called a RABS. Not every “generation” is a hardware leap—some are the industry catching up to a definition.

That distinction matters for what comes next. 

FOUR INGREDIENTS LOOKING FOR A NAME

Nobody has formally declared a 5th generation of barrier technology the way the 2013 piece declared the 4th. But four separate, well-documented developments have matured enough since 2013 that the case is worth making—each one extending exactly the logic of the generation before it, one step further.

The barrier itself goes single-use.

Fourth-generation SUDS made the parts inside the isolator disposable. What's emerged since is the isolator enclosure itself becoming flexible, single-use film—eliminating the rigid shell's cleaning validation and changeover burden entirely for many applications, not just its internal components. UK-founded ONFAB (with US manufacturing) and Italy's CSV Containment build flexible isolators rated to OEB5 using tear-resistant antistatic polyurethane film; ILC Dover—originally a spacesuit-materials company—expanded into the space through its acquisition of the UK's Solo Containment. On the transfer side, continuous-liner-and-crimp systems (LUGAIA's SafeSeal is one current example) apply the same single-use logic to the material path itself, sealing a liner closed at OEB5 integrity without a rigid chamber at all.

Robots replace the glove.

Every prior generation isolated the human from the process while still requiring a human hand inside a glove port to do the work. The next logical step—removing the hand entirely—is not hypothetical. Vanrx Pharmasystems (now part of Cytiva) commercialized its first gloveless, fully robotic aseptic filling isolator in 2013, the same year the “4th generation” piece was published. Its SA25 Workcell and smaller Microcell platform use six-axis robotics and machine vision to perform filling, capping, and container handling with no glove ports, no mouse holes, and—per Cytiva's own framing—no human-generated particulate at all. AST's ASEPTiCell and GENiSYS platforms follow the same logic. Fujifilm Diosynth invested in gloveless robotic isolators specifically to expand gene therapy and viral vaccine fill-finish capacity—a direct line back to the smaller-batch, higher-value molecules driving this whole shift.

PAT closes the loop in real time.

Process Analytical Technology—in-line spectroscopy, continuous particle and environmental monitoring, and automated glove-integrity sensing—is replacing the periodic manual check with continuous data. Where 3rd- and 4th-generation isolators relied on scheduled leak tests and end-of-batch quality review, PAT-integrated systems feed live data into electronic batch records and quality systems as the batch runs, catching a containment breach or environmental excursion in the moment rather than after the fact.



Facilities become podular.

The fixed, single-product cleanroom is a poor match for a CDMO or cell-and-gene therapy manufacturer serving a dozen different clients and modalities in the same year. G-CON Manufacturing's POD® cleanrooms—prefabricated, factory-tested, and genuinely mobile (they move on air bearings and have been relocated between sites)—are purpose-built for exactly this reality, and the company's own positioning leans heavily on multi-product CDMO and cell-and-gene therapy demand. A facility that can be reconfigured in months rather than rebuilt from scratch is the facility-level expression of the same problem SUDS solved at the component level a decade earlier: don't rebuild the whole system for the next product, just swap the part that touches it.

5G ISOLATION SYSTEMS: ARE WE THERE YET?

Individually, none of these four developments is brand new—Vanrx's first commercial system dates to 2013, the same year the 4th generation was named. What's changed is that all four are now mature enough and increasingly deployed together, so they start to look less like isolated innovations and more like a coherent answer to a single question: how do you contain an OEB5 molecule, made in a 300-unit batch, for a CDMO that will be running a completely different product and modality next quarter? That's a different problem than the one 3rd- and 4th-generation isolators were built to solve. Those generations answered, “How do we keep a fixed-product aseptic line clean and safe? ”The emerging generation is answering, “How do we build containment that's as flexible, disposable, and reconfigurable as the pipeline itself has become? —which is arguably a more fundamental shift than catalytic VHP conversion or single-use tubing ever was.



Whether that constitutes a true “5th generation” in the formal sense the 2013 article claimed for the 4th, or simply four parallel trends still waiting for a defining moment, is a fair question—and an open one. But the direction is hard to argue with: smaller batches, higher potency, higher value, and a manufacturing base that increasingly serves many masters rather than one. Barrier technology has reinvented itself to match that reality every decade for thirty years. There's little reason to think this decade is the exception.

A note on rigor: this piece traces a real, sourced history — particularly the four generations detailed in the 2013 “Emerging Fourth Generation Barrier Technologies” piece — but the “5th generation” framing is the author's own synthesis, not an established industry consensus. Treat it as an informed argument worth debating, not a settled taxonomy.

FURTHER READING / SOURCES

• “Emerging Fourth Generation Barrier Technologies,” IPS Insights, Feb. 2013
• “HPAPI: When Less is More,” Contract Pharma (Tom Patnaik, 2011/2012)
• “The future is gloveless for biopharma aseptic filling,” Cleanroom Technology
• “New Tech Disrupts Traditional Aseptic Processing,” PDA Letter
• Cytiva/Vanrx: “A closed robotic workcell, not just a gloveless isolator”
• G-CON Manufacturing, POD® Cleanroom
• ONFAB, CSV Containment, ILC Dover (Flexible Isolator Specifications)